General Information of Drug (ID: DMG0SPO)

Drug Name
CS-0777 Drug Info
Synonyms
CS-0777; UNII-KCH74QG79A; KCH74QG79A; 827344-05-8; CS 0777; SCHEMBL1454408; CHEMBL1951587; YXEQXPNSBUIRDZ-OAQYLSRUSA-N; ZINC59872504; 1192731-63-7; 1-Butanone, 1-(5-((3R)-3-amino-4-hydroxy-3-methylbutyl)-1-methyl-1H-pyrrol-2-yl)-4-(4-methylphenyl)-
Indication
Disease Entry ICD 11 Status REF
Multiple sclerosis 8A40 Phase 1 [1]
Cross-matching ID
PubChem CID
11371290
CAS Number
CAS 827344-05-8
TTD Drug ID
DMG0SPO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Siponimod DM2R86O Multiple sclerosis 8A40 Approved [3]
Fingolimod DM5JVAN Multiple sclerosis 8A40 Approved [4]
Ozanimod DMT6AM2 Multiple sclerosis 8A40 Approved [5]
Etrasimod DMT0A3Y Ulcerative colitis DD71 Approved [6]
Ponesimod DMEAOYJ Multiple sclerosis 8A40 Approved [7]
MT-1303 DMSE9TH Crohn disease DD70 Phase 2 [8]
ONO-4641 DMLUM3Y Rheumatoid arthritis FA20 Phase 2 [9]
KRP-203 DMOW9X2 Cutaneous lupus erythematosus EB5Z Phase 2 [9]
VTX-002 DMZ8Z5A Ulcerative colitis DD71 Phase 2 [10]
CBP-307 DM3TH6Y Ulcerative colitis DD71 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sphingosine-1-phosphate receptor 1 (S1PR1) TT9JZCK S1PR1_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT00616733) 12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients. U.S. National Institutes of Health.
2 Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist. ACS Med Chem Lett. 2011 Mar 2;2(5):368-72.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
8 Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs. 2015 Jul;29(7):565-75.
9 Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
10 Clinical pipeline report, company report or official report of Ventyx Biosciences
11 Clinical pipeline report, company report or official report of Connect Biopharma